Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Om39.0
Omega-3 – Forschung
Hilft vermutlich
3.142 begutachtete Studien
Die 989 neuesten von 3142 Studien werden angezeigt.
Omega-3 scheint in 15 von 20 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2015–2026 mit einer typischen Studiengröße von 251 Teilnehmenden.
Basierend auf 984 Studien · 276 Meta-Analysen · 578 RCTs · 550,423 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
15geholfen4unklar1nicht geholfen· 964 weitere ohne bewertete Effektdaten
Nach Outcome
Heart & blood pressureVerbesserte Triglyceride und kardiovaskuläre Marker innerhalb von 4-8 Wochen · 4-8 Wochen
Hilft wahrscheinlich825 Studien
Therapeutic & clinical
Hilft wahrscheinlich146 Studien
Women's healthLiefert essenzielle Nährstoffe für eine gesunde Schwangerschaft · Fortlaufend · Kann helfen, Menstruationsbeschwerden und PMS-Symptome zu reduzieren · 1-3 Zyklen · Entzündungshemmende Unterstützung während des menopausalen Übergangs · 4-8 Wochen
Hilft wahrscheinlich108 Studien
Cognitive functionDHA ist ein entscheidender struktureller Bestandteil des Gehirns und unterstützt das Gedächtnis · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung59 Studien
Glucose & metabolicVerbessert das Lipidprofil und verbessert die Insulinsensitivität moderat · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung47 Studien
Cholesterol & lipidsVerbesserte Triglyceride und kardiovaskuläre Marker innerhalb von 4-8 Wochen · 4-8 Wochen
Sleep & insomniaHöherer Omega-3-Status ist mit besserer Schlafqualität assoziiert · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung3 Studien
In Zahlen
Aus 55 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
85%
über Studien hinweg
Untersuchte Personen
550k
typische Studie: 251 Personen
Stärkste Designs
854
276 gepoolt, 578 randomisiert
Zeigte Nutzen
75%
15/20 Studien
Wie lange Studien liefen
1–3 Monate
2
3+ Monate
6
Untersuchte Populationen
General population4
Cardiovascular patients3
Adults2
Pregnant women2
Aktives Forschungsgebiet
742 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
201520202026
1muscle strength, endurance, and recoveryMeta-Analysen=1,211 · large study2026
Einfach gesagt: These findings reveal an outcome-specific efficacy pattern supporting targeted supplementation strategies aligned with primary training objectives in athletic populations.
Wang Z et al. · Nutrients (2026)
The analysis incorporated 35 trials enrolling 1211 participants.
Network consistency assessment revealed no significant disagreement between direct and indirect evidence across all outcomes.
These findings reveal an outcome-specific efficacy pattern supporting targeted supplementation strategies aligned with primary training objectives in athletic populations.
2Depressive disorder symptomsMeta-Analysen=17,437 · very large study2025
Einfach gesagt: This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
Cheng YC et al. · Psychological medicine (2025)
Adjunctive nutraceuticals consistently showed better efficacy than antidepressants (ADT) alone in outcomes including SMD, remission, and response.
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
3Ankle-brachial indexMeta-Analysen=1,830 · large study2024
Einfach gesagt: The evidence is very uncertain about the effect of omega-3 fatty acids in people with intermittent claudication on quality of life, walking distance (pain-free or maximal), ankle-brachial index, and the incidence of revascularisation procedures or frequency of amputation in the lower limb.
Mohammady M et al. · The Cochrane database of systematic reviews (2024)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
The evidence is very uncertain about the effect of omega-3 fatty acids in people with intermittent claudication on quality of life, walking distance (pain-free or maximal), ankle-brachial index, and the incidence of revascularisation procedures or frequency of amputation in the lower limb.
The evidence suggests that omega-3 results in little to no difference in adverse events.
4Anxiety and depressionMeta-Analysen=1,426 · large study2023
Einfach gesagt: Only one study reported significant reduction in anxiety severity with 2.1 g/day EPA (85.6% of total EPA + DHA), therefore meta-analysis was not possible.
Kelaiditis CF et al. · Prostaglandins, leukotrienes, and essential fatty acids (2023)
Only one study reported significant reduction in anxiety severity with 2.1 g/day EPA (85.6% of total EPA + DHA), therefore meta-analysis was not possible.
These results support the therapeutic potential of EPA in depression at proportions ≥ 60% of total EPA + DHA and doses ≥ 1 g/day and < 2 g/day.
5Depressive symptomsSystematische Übersichtn=4,500 · very large study2021
Einfach gesagt: Our primary analyses may suggest a small-to-modest, non-clinically beneficial effect of n-3PUFAs on depressive symptomology compared to placebo; however the estimate is imprecise, and we judged the certainty of the evidence on which this result is based to be low to very low.
Appleton KM et al. · Cochrane Database of Systematic Reviews (2021)
At present, we do not have sufficient high-certainty evidence to determine the effects of n-3PUFAs as a treatment for MDD.
Primary analyses may suggest a small-to-modest, non-clinically beneficial effect of n-3PUFAs on depressive symptomology compared to placebo.
More complete evidence is required for both the potential positive and negative effects of n-3PUFAs for MDD.
6Adiponectin levelsMeta-Analysen=4,568 · very large study2022
Einfach gesagt: The evidence supports a beneficial effect of omega-3 FAs intake on serum adiponectin levels but does not appear to impact on leptin concentrations.
Sepidarkish M et al. · Critical reviews in food science and nutrition (2022)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Omega-3 FAs intake was associated with a significant increase in plasma adiponectin levels (n = 43; 3,434 participants; SMD: 0.21, 95% CI: 0.04, 0.37; p = 0.01; I2= 80.14%).
However, omega-3 FAs intake had no significant effect on leptin levels (SMD: -0.02, 95% CI: -0.20, 0.17, I2= 54.13%).
The evidence supports a beneficial effect of omega-3 FAs intake on serum adiponectin levels but does not appear to impact on leptin concentrations.
Einfach gesagt: The find-ings highlight the heterogeneity in responses to omega-3 fatty acid supplementation and emphasize the need for cautious interpretation.
Fei L et al. · Asia Pacific journal of clinical nutrition (2024)
The meta-analysis revealed a neutral overall effect size of omega-3 fatty acid supplementation on proteinuria levels, assessed under both common and random effect models.
Despite the lack of statistically significant evidence supporting the efficacy of omega-3 fatty acids in reducing proteinuria, the variability in interventions and patient populations suggests potential individual responses.
The find-ings highlight the heterogeneity in responses to omega-3 fatty acid supplementation and emphasize the need for cautious interpretation.
8Cardiovascular events and coronary revascularizationMeta-Analysen=144 · medium study2024
Einfach gesagt: Omega-3 fatty acid supplementation reduced the risk of cardiovascular events and coronary revascularization, regardless of background statin use.
Dinu M et al. · European journal of preventive cardiology (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Lower risk was still observed in trials where most participants (≥60%) were on statin therapy.
Compared with DHA + EPA, EPA alone showed a further significant risk reduction of revascularizations (0.76, 95% CI 0.65-0.88; P = 0.0002; P-interaction = 0.005) and all outcomes except HF.
Omega-3 fatty acid supplementation reduced the risk of cardiovascular events and coronary revascularization, regardless of background statin use.
10Depressed moodMeta-AnalyseCited 50×n=4,605 · very large study2018
Einfach gesagt: In the well-being mental health group, the Hedges g was 0.12 (95% confidence interval, -0.05 to 0.29), which indicated no significant effect of n-3 PUFA supplementation on depressed mood compared w...
Bae JH et al. · Nutrition research (New York, N.Y.) (2018)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
In the well-being mental health group, the Hedges g was 0.12 (95% confidence interval, -0.05 to 0.29), which indicated no significant effect of n-3 PUFA supplementation on depressed mood compared with placebo.
In the depressive group, the pooled Hedges g was -0.94 (95% CI, -1.37 to -0.50]) for the random-effects model, which indicated a large effect of n-3 PUFA supplementation on those with depressed mood compared with placebo.
Although this review shows that omega-3 fatty acids are effective in the treatment of elderly depressed patients, the benefits of omega-3 fatty acid supplementation were significant only in the elderly patients with mild to moderate depression.
11Patient important outcomes after myocardial infarctionMeta-AnalyseCited 15×n=24,414 · very large study2019
Einfach gesagt: For adult patients with AMI, omega 3 fatty-acids probably yield no benefit to patient important outcomes.
Popoff F et al. · BMC cardiovascular disorders (2019)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Regarding adverse events, we are uncertain if Omega 3 fatty acids improve/reduce non severe adverse events (RR 1.39 95% CI 0.36 to 5.34; very low certainty).
There is probably little or no difference in the outcome suspension due to adverse events (RR 1.19 CI 95% 0.97 to 1.47; moderate certainty).
For adult patients with AMI, omega 3 fatty-acids probably yield no benefit to patient important outcomes.